Acquisition of Affiniti

Adventis Group PLC
16 December 2004


                               Adventis Group plc

                        Acquisition of Affiniti (UK) Ltd


16 December 2004

Adventis Group plc ('Adventis'), the specialist multimedia and marketing agency,
is pleased to announce that it has agreed terms for the acquisition of 100% of
the shares of Affiniti (UK) Ltd ('Affiniti'), a leading marketing, design and
advertising agency within the healthcare sector.

Adventis, which floated on AIM in July 2004 with a placing that raised £3.0
million before expenses for the Company, has stated its intention to diversify
into a number of different, but related, business streams. The healthcare
sector, where Adventis has an existing foothold, was identified as such a
sector. By acquiring Affiniti, Adventis intends to build on this base and
significantly expand its operations in the healthcare sector.

Information on Affiniti

Affiniti has been trading successfully for four years to become a significant
player amongst  independent healthcare agencies in the UK. Employing 20 staff
Affiniti will continue to operate from its base in Chesham, Buckinghamshire. It
has a solid base of blue chip pharmaceutical clients including: Allergan,
Aventis Pasteur MSD, Chiron Vaccines, Eden Biopharm, Leo Pharma, and Serono.

The on-going services of Affiniti's founding directors and management team,
Stuart Tennant, John Garner, Chas Burton and Neil Smith have been successfully
secured.  Affiniti has recently strengthened its management team with Chris
Doyle joining as commercial director from Napp Pharmaceuticals.  Chris will be
responsible for brand strategy and planning.

Details on the acquisition

Adventis is paying a base consideration of £1,129,748, which represents a
multiple of 7.5 times pre-tax profit of £150,632 for the year ending 31 May
2004, after adjusting for £49,781 of non-recurring costs in the period. There
will be an additional cash payment for an amount equal to the value of
Affiniti's audited net assets at completion (the 'Net Asset Amount'). The
audited turnover and pre tax profit for Affiniti for the year ending 31 May 2004
were £1,820,073 and £100,851 respectively. If profits grow from their present
level, the management of Affiniti can earn further payments amounting to 3.3
times of the annual excess over the next three years, up to a maximum total
consideration of £3.5 million (including the Net Asset Amount). Further details
of the structure of the payments are included in the footnote below.

Managing Director of Affiniti, Stuart Tennant commented, 'The Affiniti board
believes this move will enable us to supply a more integrated offering by
building up the services currently provided by Affiniti and adding additional
capacity to meet the evolving needs of the healthcare industry.'

Charles Phillpot, CEO of Adventis stated, 'We have sought to expand our existing
business in the healthcare sector and have examined many potential partners.
Affiniti were chosen due to their outstanding client base, level of management
experience and the excellence of the service they offer. We are confident of the
contribution that Affiniti will bring to Adventis in 2005. We look forward to
announcing further corporate activity in due course.'



Enquiries:

Charles Phillpot, Managing Director               Sarah Gestetner, Fiona Mulcahy
Adventis Group plc                                Citigate Dewe Rogerson
Tel: [phone]                                Tel: [phone]

Paul Dudley
WH Ireland Limited
Tel: [phone]



Footnote:

The base consideration £1,129,748 will be split in a 60:40 ratio as to cash and
shares, with an initial payment of £452,122 in cash and £301,417 in shares to be
issued at the average of the market price per share of Adventis in the five
business days prior to completion, which will take place on 4th January 2005.
The balance is phased equally as three annual payments of £75,241 in cash and
£50,161 in shares.

The Net Asset Amount will be satisfied by an initial cash payment of £430,135
payable on completion. Following the audit of Affiniti's assets, any variance
between this amount paid and the Net Asset Amount will be repayable by the
vendors of Affiniti or payable by Adventis as the case may be. The net assets of
Affiniti primarily consist of current assets.

The earnout will be paid in a 60:40 ratio as to cash and shares with annual
payments based on the audited results for each of the next three financial
years.

All share payments post completion will be allotted at the average market price
per share of Adventis for the five days prior to their issue. Adventis retains
the right to pay any share consideration in cash at its sole discretion.


                      This information is provided by RNS
            The company news service from the London Stock Exchange